{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:06:58Z","timestamp":1788217618647,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejca.2019.07.022","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T17:51:55Z","timestamp":1567187515000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-3521","authenticated-orcid":false,"given":"Heejung","family":"Chae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deokhoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-8455","authenticated-orcid":false,"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heung-Moon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Won","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Soo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-6007","authenticated-orcid":false,"given":"Seung-Mo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.07.022_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2407-2-10","article-title":"Worldwide trends in mortality from biliary tract malignancies","volume":"2","author":"Patel","year":"2002","journal-title":"BMC Canc"},{"key":"10.1016\/j.ejca.2019.07.022_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.07.022_bib3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2019.07.022_bib4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2019.07.022_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jmoldx.2018.09.005","article-title":"Mutation burden and I index for Detection of microsatellite instability in colorectal cancer by targeted next-generation sequencing","volume":"21","author":"Kim","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2019.07.022_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/path.4978","article-title":"Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis","volume":"244","author":"Hwang","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2019.07.022_bib7","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2019.07.022_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2019.07.022_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ejca.2019.07.022_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2019.07.022_bib11","article-title":"OncoKB: a precision Oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib12","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2019.07.022_bib13","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.07.022_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tranon.2016.01.007","article-title":"Genomic alterations in biliary tract cancer using targeted sequencing","volume":"9","author":"Yoo","year":"2016","journal-title":"Trans Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib15","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.07.022_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2019.07.022_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2017.05.006","article-title":"Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground?","volume":"81","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.07.022_bib18","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/cncr.30247","article-title":"Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance","volume":"122","author":"Ahn","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2019.07.022_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2019.07.022_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.030","article-title":"LBA28 Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions","volume":"29","author":"Javle","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib21","volume":"29","author":"Hollebecque","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib22","article-title":"624PD Preliminary results of a ph2a study to evaluate the clinical\u00a0efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA)","volume":"29","author":"Chen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib23","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2017.35.15_suppl.4015","article-title":"Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts","volume":"35","author":"Lowery","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib24","doi-asserted-by":"crossref","first-page":"TPS545","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS545","article-title":"ClarIDHy: a phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation","volume":"36","author":"Abou-Alfa","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","article-title":"Biliary tract cancer: state of the art and potential role of DNA damage repair","volume":"70","author":"Lamarca","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2019.07.022_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib27","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","article-title":"Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX","volume":"24","author":"Sehdev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.07.022_bib28","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.07.022_bib29","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2019.07.022_bib30","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2018.36.4_suppl.263","article-title":"Variations in DNA repair genomic alterations and tumor mutation burden in biliary tract cancer (BTC) subtypes","volume":"36","author":"Abdel-Wahab","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib32","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1158\/1078-0432.CCR-16-0247","article-title":"Biomarkers of response and resistance to DNA repair targeted therapies","volume":"22","author":"Stover","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2019.07.022_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the Oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.07.022_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2019.07.022_bib35","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1158\/1538-7445.AM2018-3437","article-title":"Abstract 3437: genomic alterations, mutation burden, and microsatellite instability status of Chinese intrahepatic cholangiocarcinoma","volume":"78","author":"Cao","year":"2018","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:55Z","timestamp":1760732695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919304307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":35,"alternative-id":["S0959804919304307"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.07.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}